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Abstract
Breast cancers detected after a negative breast screening examination and prior to the next 
screening are referred to as interval cancers. These cancers generally have poor clinical 
characteristics compared to screen-detected cancers, but associations between interval cancer and 
genomic cancer characteristics are not well understood. Mammographically-screened women 
diagnosed with primary invasive breast cancer from 1993-2013 (n=370) were identified by linking 
the Carolina Breast Cancer Study and the Carolina Mammography Registry. Among women with 
a registry-identified screening mammogram 0-24 months before diagnosis, cancers were classified 
as screen-detected (N=165) or interval-detected (N=205). Using logistic regression, we examined 
the association of mode of detection with cancer characteristics (clinical, IHC, and genomic), 
overall, and in analyses stratified on mammographic density and race. Interval cancer was 
associated with large tumors (> 2 cm) (OR=2.3; 95% C.I.: 1.5, 3.7), positive nodal status (OR=1.8; 
95% C.I.: 1.1, 2.8), and triple negative subtype (OR=2.5; 95% C.I.: 1.1, 5.5). Interval cancers were 
more likely to have non-Luminal A subtype (OR=2.9; 95% C.I.: 1.5, 5.7), while screen-detected 
cancers tended to be more indolent (96% had low risk of recurrence genomic scores; 71% were 
PAM50 Luminal A). When stratifying by mammographic density and race, associations between 
interval detection and poor prognostic features were similar by race and density status. Strong 
associations between interval cancers and poor-prognosis genomic features (non-Luminal A 
subtype and high risk of recurrence score) suggest that aggressive tumor biology is an important 
contributor to interval cancer rates.
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INTRODUCTION
The purpose of screening is to diagnose cancer at an earlier more treatable stage, thereby 
reducing mortality(1,2). Mammography, the most widely used breast cancer screening 
method, has been shown to reduce breast cancer mortality in both randomized control 
trials(3,4) and population-based screening programs(5,6). Interval cancers, which represent a 
weakness of mammographic screening, are defined as cancers detected after a negative 
mammogram in the interval between regular screenings. These cancers tend to be higher 
stage and grade at the time of diagnosis whereas screen-detected cancers have been reported 
to have more indolent molecular characteristics(7–10). The proportion of interval cancers in 
screened populations varies from 14% to 38%(11–14), depending on screening interval and 
underlying population breast cancer incidence rates(15).
Interval cancers are believed to arise from multiple scenarios. First, interval cancers may be 
cancers that existed at the time of screening but were not detected (false negatives). Some 
missed tumors are believed to be caused by masking bias, wherein high mammographic 
density can conceal a tumor from being detected(16,17); it is also possible that radiographic 
features of the cancer may influence detection(18). Second, interval cancers may represent 
cancers that were not present at the time of screening, but possess aggressive tumor 
characteristics that enable them to grow to a detectable level before the next screening. 
Understanding how biologic characteristics and masking contribute to the rate of interval 
cancer could help in the development of new technologies such as 3D-mammography.
In this study, we examined the molecular characteristics (immunohistochemical and RNA-
based) of interval cancers. Previous studies have shown that interval cancers have a more 
aggressive profile with respect to clinical factors such as estrogen receptor (ER), 
progesterone receptor (PR), or human epidermal growth factor (HER)2-status(8,13), but 
only one study has reported associations between interval cancer and RNA-based genomic 
subtype such as the PAM50 intrinsic subtype(19). No study to our knowledge has reported 
associations for the genomic risk of recurrence (ROR-PT) score based on PAM50. Given 
that genomic tests are increasingly utilized in clinical settings, it is important to understand 
the relationship of interval detection to these genomic characteristics.
METHODS
Data Sources
Carolina Breast Cancer Study—The Carolina Breast Cancer Study (CBCS) is a 
population-based study designed to identify both genetic and environmental risk factors for 
breast cancer among North Carolina women(20). The current analysis uses data from all 
three study phases of CBCS (Phase 1, 1993-1996; Phase 2, 1996-2001; and Phase 3, 
2008-2013). Randomized recruitment was used to oversample both African American and 
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younger cases (under age 50)(21,22) in all phases. The first two phases of CBCS recruited 
both cases and controls from 24 counties of eastern and central NC(20). Cases were women 
aged 20 to 74 diagnosed with a primary invasive breast cancer between May 1, 1993 and 
December 31, 2000 and identified through rapid case ascertainment from the North Carolina 
Central Cancer Registry. Cases of in situ cancer were also enrolled in Phase 2. There was a 
total of 2311 cases (1803 invasive cases, 508 in situ cases) enrolled in Phases 1&2. Phase 3 
recruited invasive cases only (N=3000) from 44 counties in NC(22).
CBCS Variables—Women in CBCS were interviewed at baseline by a nurse, at which 
point they also provided written consent for medical record requests. All measures were self-
reported, except BMI, which was nurse-measured. All demographic/patient (age at 
diagnosis, race, menopausal status, education, income, first degree family history of breast 
cancer, marital status, and hormone replacement (HRT) use), clinical (tumor size, nodal 
status, and stage), and molecular data used in this study came from CBCS.
The following IHC markers were used to distinguish intrinsic subtype: ER, PR HER2, 
human epidermal growth factor-1 (HER1), and cytokeratin 5/6 (CK5/6), and tumor 
suppressor p53. For Phases 1&2 of CBCS, previously described assays were used for these 
IHC markers(23–25). ER and PR status were determined from medical records for the 80% 
of women who had these data available from medical records(23); for the remaining cases 
with paraffin-embedded tissue available, IHC analysis was performed at the University of 
North Carolina Translational Pathology Laboratory (TPL). Positivity for ER and PR status 
were defined as having more than 5% of cells showing nuclei-specific staining(24). Tumors 
with HER2 staining in more than 10% of cells were considered HER2 positive(25). 
Positivity of EGFR was defined as any HER1 staining and positivity for CK 5/6 was defined 
as any cytoplasmic and/or membranous staining. Methods to distinguish intrinsic subtypes in 
CBCS Phase 3 are described in detail by Allott et al.(26). Briefly, tissue microarrays 
(TMAs) were constructed and stained by TPL and were digitally imaged using the Aperio 
ScanScope XT (Aperio Technologies, Vista CA). Automated digital image analysis was 
performed to quantify IHC staining using a Genie classifier and the Nuclear V9 algorithm 
(Aperio Technologies, Vista CA), for ER and PR and a Genie classifier and Membrane V9 
algorithm for HER2. Three-marker intrinsic subtypes were defined using ER, PR, and HER2 
status as described by Allott et al.(26): Luminal A (ER+ and/or PR+, HER2−), Luminal B 
(ER+ and/or PR+, HER2+), HER2+ (ER−, PR−, HER2+) and triple negative (ER−, PR−, 
HER2−). Five-marker intrinsic subtypes were assigned to women who had complete data for 
ER, PR, HER2, CK5/6 and HER1 as described by Carey et al.(24), where the three markers 
were used for Luminal and HER2 cancers, but basal-like cancer required positivity for either 
HER1 or Ck5/6 (ER−, PR−, HER2−, HER1+ or CK5/6+). p53 positivity for IHC was 
defined as dark nuclear protein staining present in 10% or more of invasive cells, all other 
cases were considered p53 negative(27).
PAM50 gene expression subtyping was performed on a subset (n=2007) of samples with 
available formalin-fixed paraffin embedded cores or unstained slides from CBCS Phases 
1-3. For samples from CBCS 1&2 (N=188), RNA was extracted from two unstained 10-μm 
FFPE slides per patient. For women in CBCS Phase 3, RNA was extracted from two 1-mm 
cores (N=377) or two 10 μm slides (N=79) as described previously(26). RNA was isolated 
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using the RNeasy FFPE Kit (Qiagen) and Nanostring analyses were performed in the Rapid 
Adoption Molecular laboratory and the Translational Genomics laboratory at UNC. Tumors 
were classified as Luminal A, Luminal B, HER2-enriched, Basal-like, and normal-like using 
the PAM50 predictor(28). RNA gene expression for p53 mutation status was determined 
using a previously published 48-gene p53 signature(29). A subset of the PAM50 genes were 
also used to construct the risk of recurrence score, taking into account proliferation and 
tumor size (ROR-PT)(30). The ROR-PT is the research correlate to the clinically used 
Prosigna assay (NanoString Technologies Inc., Seattle, WA, USA), which has been clinically 
validated(31). The ROR-PT is a continuous score, but can be categorized (Low/Medium/
High) using published protocols(28).
Carolina Mammography Registry—The Carolina Mammography Registry (CMR)(32) 
is a large community-based mammography registry that has studied the performance and 
outcomes of mammography in North Carolina since 1994 and participates in the Breast 
Cancer Surveillance Consortium (BCSC)(33). The CMR collects data from breast imaging 
facilities across North Carolina. Data from patients and radiologists include patient 
demographics, prior screening history, breast cancer risk factors including family history of 
breast cancer, radiologist-reported breast density using Breast Imaging Reporting and Data 
System (BI-RADS) classifications, reason for the visit, screening and diagnostic procedures 
performed, and radiologists’ interpretation of the examination using BI-RADS assessment 
categories and the recommended follow-up. Mammographic modality was available for the 
majority of patients (74%, N=186), and among these women, 75% had digital 
mammography and 25% had screen-film mammography.
CMR Variables—All mammography data used in this analysis, including mammographic 
density, type of examination, screening dates, and screening outcomes came from the CMR. 
In the CMR, mammographic density is recorded at each mammogram by the interpreting 
radiologist using BI-RADS. For all analyses, mammographic density was categorized as 
non-dense (BI-RADS 1 and 2) and dense (BI-RADS 3 and 4)(34).
Mammogram findings were reported by the radiologists in CMR using BI-RADS 
assessment categories(35). Screening mammograms and results were defined using BCSC 
definitions(36). A mammogram was considered to be screening if: the woman was 18 or 
older, had no breast implants or prior mastectomy, no history of breast cancer, the indication 
for the examination was routine screening, it was the first examination sequence of the day, 
bilateral screening views were done, there was no imaging in the previous 9 months, and the 
overall assessment code was not BI-RADS 6. A positive screening mammogram is defined 
as a screening mammogram with a BI-RADS assessment code of 4 (suspicious abnormality) 
or 5 (highly suggestive of malignancy). Screening mammograms with a BI-RADS 
assessment code of 0 (incomplete) or 3 (probably benign finding) with a recommendation 
for biopsy, fine needle aspiration (FNA), or surgery were also considered positive. A 
negative screening mammogram was defined as a screening mammogram with a BI-RADS 
assessment category of 1, 2, or 3 with no recommendation for biopsy, FNA, or surgery.
CBCS-CMR Linkage—Study approval was granted by the University of North Carolina 
Institutional Review Board. All cases and controls from Phases 1, 2 and 3 of CBCS 
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(N=7331) were matched to women in CMR from 1994-2014 inclusive (N=657,060) using 
probabilistic linkage. The following identifiers were used to match records: last four digits 
of social security number (SSN), first name, last name, middle initial, date of birth, and 
address. Because some women in CBCS Phase 3 did not consent to use of SSNs, Phase 3 of 
CBCS was linked separately for those with and those without SSN.
Matches (women that were in both CBCS and CMR) were determined using thresholds set 
on linking probabilities of the identifiers chosen. The final linked dataset included 2,614 
women (871 controls and 1,743 cases of DCIS or invasive breast cancer). The sensitivity of 
linkage (100%) was the same for women linked with SSN information and those linked 
without, but specificity was higher (97.1% vs. 95.2%) for those with SSN. Linkage was 
performed by the Cancer Information and Population Health Resource (CIPHR) at the 
University of North Carolina(37). Consistent with screening patterns in the general 
population, CBCS women with records in the CMR were more likely to be cancer cases, 
older, post-menopausal, and have used hormone replacement therapy.
Eligibility Criteria—The eligibility criteria applied in this study are shown in 
Supplemental Figure 1. As a secondary quality control measure for the linkage, information 
from one commonly collected variable between the two data sets, date of diagnosis, was 
compared. Both CBCS and CMR collected data for this variable from the NC Central 
Cancer Registry; date of diagnosis should therefore be the same if the match from the 
linkage was correct. There were 15 of 1512 (0.1%) women where dates of diagnosis did not 
match. After manual review, it was determined that these women represented false matches 
and these women were excluded from analysis. The linked dataset contained 1497 women. 
43% of these women (N=644) had genomic data available.
Defining Interval vs. Screen-detected Cases—Invasive breast cancer cases were 
classified as interval- or screen-detected based on the date of the most recent pre-diagnostic 
screening mammogram and the date of breast cancer diagnosis. Screening interval 
recommendations varied from 1-2 years(38–41) during the study period (1993-2013). Mode 
of detection was defined using both a 12 and 24 month screening interval (Figure 1). For 
example, using the 24 month screening interval, if a positive screening mammogram was 
recorded in the 24 months before the diagnosis date, the cancer was classified as screen-
detected. If a negative screening mammogram was recorded in the 24 months before 
diagnosis, the cancer was classified as interval cancers. The 24 month interval was chosen 
for the main analysis to reflect current screening recommendations and to enhance 
comparability with other studies(8,12,16,42,43).
Of the 1,497 women with a primary invasive breast cancer in the CMR-CBCS data set, we 
identified 165 women who were screen-detected and 205 women who were interval-detected 
within two years of a negative screening mammogram. Sensitivity analyses that decreased 
the screening interval to 12 months were also performed; using this shorter interval, 161 
women were classified as screen-detected and 107 women were classified as interval-
detected. Women who met neither screen-detected nor interval-detected definitions were 
classified as “unknown”. Compared to screen-detected women, women with unknown mode 
of detection had less screening history in the linked dataset, were more likely to be <50 
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years old and premenopausal. Women with unknown mode of detection were excluded from 
all analyses.
Statistical Analysis
Logistic regression was used to calculate univariate odds ratios for associations for each of 
the demographic/patient variables (age, race, BMI, CBCS Phase, menopausal status, 
education, marital status, income, family history, hormone replacement therapy use, and 
mammographic density) with mode of detection, with screen-detected cancers being used as 
the referent group. Potential confounders were chosen a priori based on a review of the 
literature. Adjusted odds ratios were calculated for the association between clinical and 
molecular variables (tumor size, nodal status, cancer stage, ER, PR, and HER2 positivity, 3-
marker subtype, 5-marker subtype IHC p53, PAM50 subtype, genomic p53) and mode of 
detection; odds ratios were adjusted for demographic/patient variables found to be strongly 
associated with mode of detection. For subtype analyses, Luminal A was used as the referent 
group. For genomic analyses, an additional analysis was done comparing Luminal A vs. 
non-Luminal A cancers (Luminal B, HER2, and basal-like).
We considered mammographie density and race as potential effect measure modifiers of the 
relationship between patient and clinical characteristics and mode of detection; as such, 
analyses for demographic/personal and clinical characteristics were repeated stratifying for 
mammographic density and race separately. In this study, we define ‘aggressive’ cancer 
characteristics according to well-established prognostic associations, such that ‘aggressive’ 
characteristics include: large tumor size (> 2 cm), high stage (Stage III/IV), positive nodal 
status, ER−, PR−, triple negative, p53 mutant, basal-like, or high ROR-PT score. All 
analyses were done in SAS version 9.3 (SAS Institute, Cary, NC).
RESULTS
The final analytic population contained 370 women. As described in Table 1, the majority of 
women were ≥ 50 years of age (60%), White (53%), postmenopausal (64%), had no first 
degree family history of breast cancer (79%), were never users of hormone replacement 
therapy (68%), and had non-dense breast tissue (55%). To assess patterns of mammography 
use, we evaluated mean number of mammography visits, mammographic exams (screening 
and diagnostic exams), and screening mammograms among all participants with at least one 
screening mammogram recorded during a prediagnostic screening interval (defined as more 
than two years before diagnosis, Table 1). Older and postmenopausal women had a greater 
number of visits, exams, and screening mammograms compared to younger and 
premenopausal women. There were no differences in mammography use by any of the other 
demographic/patient factors examined.
Table 2 shows associations between interval-detected vs. screen-detected cancers and 
clinical characteristics. Younger age (<50 years old, OR=1.44; 95% C.I.: 0.95, 2.20), 
premenopausal status (OR= 1.14; 95% C.I.: 0.94, 1.75), and dense breast tissue (OR=2.02; 
95% C.I.: 1.29, 3.16) were associated with interval detection (Supplemental Table 1), and all 
analyses for clinical characteristics are adjusted for age and menopausal status. Interval 
cancers were associated with aggressiveness as measured by tumor size, stage, and nodal 
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status. Interval cancers were also more commonly hormone receptor negative, but these 
results were not significant, nor was an association with p53 status. However, interval 
cancers were statistically significantly associated with triple negative status (OR= 2.45; 95% 
C.I: 1.10, 5.47) and with basal-like cancer (OR=2.06; 95% C.I: 1.07, 3.95) (Table 3). 
Associations between mode of detection and molecular variables (ER, PR, HER2, triple 
negative, basal-subtype) were unchanged after adjusting for tumor size, stage, and nodal 
status. Interval cancers were strongly associated with genomic markers (Table 3), including 
PAM50 non-Luminal A subtype (OR=2.94; 95% C.I.: 1.52, 5.71) and PAM50 basal-like 
subtype (OR=2.68; 95% C.I.: 1.21, 5.94). Mean ROR-PT score was significantly higher in 
interval than screen-detected cancers (mean =41.0 vs. 26.0; p <0.001). As shown in Figure 2, 
the kernel density distribution is shifted toward higher risk tumors among interval cancers 
and a higher proportion of ROR-PT high risk tumors, (24/105, 23%) were detected among 
interval-detected cancers (vs. 3/71, 4% among screen-detected). Associations between 
interval detection and tumor characteristics were not markedly changed when stratified by 
density (Table 2) or race (Supplemental Table 2), or by screening interval (Supplemental 
Table 3). Furthermore, to evaluate the impact of length-bias on differences between screen- 
and interval-detected cancers, we performed sensitivity analyses restricting the screen-
detected population to only those women for whom we had multiple mammograms >2 years 
prior to diagnosis (N=76). The results in this group were not substantially different in 
magnitude, but had reduced precision.
DISCUSSION
Identification of the predictors and characteristics of interval cancers contributes to our 
knowledge of the risks and benefits of mammography. We found that standard clinical 
prognosis features are associated with interval cancers, and that genomic tests indicative of 
poor prognosis are more common among interval cancers. Previous literature has shown that 
interval cancers tend to have negative prognostic characteristics (8,12,13,16,42,43), however 
we found associations to be weaker than reported previously for ER− or PR−(12,43), triple 
negative(8,42,43), and p53 mutant(43). With the exception of triple negative subtype, none 
of these were significantly associated with interval detection.
While multi-gene classification methods have become more prominent clinically, genomic 
characteristics of interval cancers are not well studied. The only study that has reported 
associations between PAM50 results and mode of detection was based within a clinical 
cancer sequencing study in Sweden with 173 patients. That study had similar findings, 
showing that interval cancer was associated with basal-like subtype(19). Higher ROR-PT 
among interval cancers has not been assessed previously. It is striking that only 4% of 
screen-detected cancers had high ROR-PT, in parallel with high frequency of Luminal A 
subtype (71%).
While our findings strongly support biologic determinants of interval cancers, masking bias 
may nonetheless contribute to interval cancer rates. Multiple studies have shown high 
mammographic density to be associated with interval cancers(44–46), including our own 
findings herein. However, it is difficult to disentangle tumor biology and mammographic 
density because younger women have both higher density and more aggressive tumor 
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characteristics(47,48). We were unable to consider the independent contributions of age, 
race, and mammographic density due to sample size.
Some limitations of the study should be noted. CMR does not include all breast imaging 
facilities in North Carolina, so only ~30% of women enrolled in CBCS were linked to CMR. 
Furthermore, CBCS oversampled younger and African American women, and therefore the 
proportion of screen and interval detected cases may vary as a function of the demographic 
and selection characteristics of CBCS(47). Therefore our study is not designed to estimate 
the proportion of screen and interval-detected cases in the general population. Notably, 
among screened women, we classified 45% of invasive cases as screen-detected. Previous 
studies based on CMR have reported higher proportions of screen detected cases (e.g. 
Henderson et al. reported 80% of cases were screen detected using a 1 year-interval(14); 
Hofvind et al. reported 60% of cases were screen detected given the 24-month definitions 
used herein(11)). We were unable to retrospectively review mammographic images to 
confirm which interval cases arose from false negatives, but we minimized misclassification 
within screen and interval-detected groups by classifying women with missing screening 
data as ‘unknown’. We note that the unknown category likely includes true screen- and 
interval-detected cases along with true clinically detected cases. We also acknowledge that 
use of BI-RADS categories to assess masking may be less sensitive than use of quantitative 
mammographic density, which was unavailable in this analysis. Despite these limitations, 
this study does provide novel data on genomic characteristics in a racially diverse 
population.
The goal of mammography is to find aggressive cancers at an earlier stage to increase 
survivorship and reduce mortality. Our research shows that a high proportion of interval 
cancers are associated with aggressive biology. Our work also suggests that genomic tests 
may be useful in distinguishing indolent vs. aggressive screen-detected cancers, given the 
high prevalence of low-risk tumors among screen-detected cases. If confirmed, these 
findings indicate that continued evaluation of genomic tools in combination with 
mammography could help to increase the benefit and reduce negative consequences of 
screening.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Mode of detection categorization, using 12 or 24 month screening interval.
1Women who had unknown mode of detection were excluded from this study.
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Kernel density distribution of PAM50 risk of recurrence (ROR-PT) score for interval- and 
screen-detected cancers. ROR distributions of screen-detected and interval-detected cancers 
are blue and red, respectively. Vertical line marks the threshold for high ROR-PT. The area 
shaded under the curve represents the proportion of cancers that have high risk of recurrence 
score. Of 105 interval-detected cancers that had genomic data available, 24 cancers (23%) 
had high ROR score. Of 71 screen-detected cancers that had genomic data available, 3 
cancers (4%) had high ROR score.
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Table 3







N (%) N (%)
3-marker subtype
 Luminal A 99 (68) 102 (55) 1.00
 Luminal B 14 (10) 16 (9) 0.95 (0.43, 2.08)
 HER2 6 (4) 7 (4) 1.12 (0.36, 3.45)
 Triple negative 26 (18) 60 (32) 2.45 (1.10, 5.47)
 Missing 20 20
5-marker subtype
 Luminal A 67 (64) 64 (47) 1.00
 Luminal B 12 (12) 30 (22) 2.45 (1.14, 5.25)
 HER2 6 (6) 4 (3) NRb
 Basal-like 19 (18) 38 (28) 2.06 (1.07, 3.95)
 Missing 61 69
PAM50
 Luminal A 51 (71) 46 (46) 1.00
 Luminal B 4 (6) 18 (18) NRb
 HER2 5 (7) 8 (8) 1.82 (0.54, 6.15)
 Basal-like 12 (17) 29 (29) 2.68 (1.21, 5.94)
 Missing 93 104
PAM50
 Luminal A 51 (71) 46 (46) 1.00
 Non-Luminal A 21 (29) 55 (54) 2.94 (1.52, 5.71)
 Missing 93 104
p53
 Wild type 42 (55) 55 (52) 1.00
 Mutant 34 (45) 51 (48) 1.13 (0.63, 2.05)
 Missing 89 99
ROR-PTc
 Low/Medium 68 (96) 81 (77) NRb
 High 3 (4) 24 (23) NRb
 Missing 94 100
a
All odds ratios are adjusted for age and menopausal status.
b
Odd ratios are not reported where cell size < 5 observations.
c
PAM50 risk of recurrence score.
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